Asensus Surgical Inc

Asensus Surgical — TransEnterix — H.C. Wainwright 22nd Annual Global Investment Conference (September 2020)

20 slides from Asensus Surgical's conference presentation, Sep 15, 2020

  1. Slide 1: H.C. Wainwright 22nd Annual Global Investment Conference

    Slide 1: H.C. Wainwright 22nd Annual Global Investment Conference

    = eenente H.C. Wainwright 22nd Annual Global nvestment Conference ithony Fernando, President & CEO = September 15, 2020

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS Wransenterix This presentation includes statements relating to the Senhance Surgical System's market development and a general corporate update. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the me

  3. Slide 3: Our Strategic Intent

    Slide 3: Our Strategic Intent

    Wransenterix | OUR STRATEGIC INTENT At TransEnterix, we believe in digitizing the interface between the surgeon and patient in laparoscopy to increase control and reduce surgical variability for improved patient outcomes in today’s value-based healthcare environment.

  4. Slide 4: Company Overview

    Slide 4: Company Overview

    WransEnterix COMPANY OVERVIEW

  5. Slide 5: Early-commercial stage company ushering in a new era of minimally invasive surgery

    Slide 5: Early-commercial stage company ushering in a new era of minimally invasive surgery

    EARLY-COMMERCIAL STAGE COMPANY USHERING IN A NEW ERAOF | TRANSENTERIX (NYSE American:TRXC) Wransenterix MINIMALLY INVASIVE SURGERY Senhance Surgical Robotic System — the first and only Digital Laparoscopy platform 7 Significant and differentiated addressable market Senhance opportunity FDA Cleared,

  6. Slide 6: Company Snapshot

    Slide 6: Company Snapshot

    COMPANY SNAPSHOT Wransenterix FIRST NEW ENTRANT IN THE FIELD OF ABDOMINAL SURGICAL ROBOTICS IN NEARLY 20 YEARS Active sites in the ieremmgarve Igutummnreene _ gareeocuscmerccuncecome U.S., E.U. and Asia 3,400+ Surgeries Performed, to date ‘Transenterix Japan Toaye jue coe Taiwan Ch 140 global employ

  7. Slide 7: Global Trends in Robotic Surgery

    Slide 7: Global Trends in Robotic Surgery

    GLOBAL TRENDS IN ROBOTIC SURGERY Wransenterix SURGICAL ROBOTICS IS ALARGE AND FAST GROWING MARKET AND LAPAROSCOPIC SURGERY ISA GREENFIELD OPPORTUNITY ~$16B A The abdominal robotic ‘surgery market is projected to grow at a double digit CAGR over the foreseeable future ~$3.7B 2018 2023 10mm Annual Abd

  8. Slide 8: Improve Outcomes, Efficiencies, and Talent Retention

    Slide 8: Improve Outcomes, Efficiencies, and Talent Retention

    IMPROVE OUTCOMES, EFFICIENCIES, AND TALENT RETENTION THE PRESSURE AND IMPACT ON SURGEONS ARE INCREASING UNDER [ VALUE-BASED HEALTHCARE IS FORCING HOSPITALS TO SS THE CONSTRAINTS OF VALUE-BASED HEALTHCARE Laparoscopy is the most widely performed surgical technique and carries limitations that compoun

  9. Slide 9: The Senhance Surgical System

    Slide 9: The Senhance Surgical System

    WransEnterix The Senhance Surgical System

  10. Slide 10: Senhance System Addresses Key Challenges Facing Hospitals and Laparoscopic Surgeons

    Slide 10: Senhance System Addresses Key Challenges Facing Hospitals and Laparoscopic Surgeons

    FACING HOSPITALS AND LAPAROSCOPIC SURGEONS [ SENHANCE SYSTEM ADDRESSES KEY CHALLENGES SF SAcenterie BUILDING THE BRIDGE FROM LAPAROSCOPY TO ROBOTICS First robotic system with ‘Augmented Intelligence (Al) ‘and Machine Vision g ‘ Capabilties > Senhance First robotic system 10 offer the security of hap

  11. Slide 11: We Are Uniquely Focused on Digital Laparoscopy

    Slide 11: We Are Uniquely Focused on Digital Laparoscopy

    WE ARE UNIQUELY FOCUSED ON DIGITAL LAPAROSCOPY >Vfransenterix: AN OPPORTUNITY AND NEED TO ADD TO THE WAYS SURGICAL ROBOTICS CREATES VALUE Wransenteric INTUITIVE Senhance Da Vinci Feature Implication Feature Implication Motion = Lap = Fully reusable = Limited Use (10x max) Instruments = 5mm and 3mm +

  12. Slide 12: Our Plan for 2020

    Slide 12: Our Plan for 2020

    WransEnterix Our Plan for 2020

  13. Slide 13: 2020 — Senhance and Digital Laparoscopy

    Slide 13: 2020 — Senhance and Digital Laparoscopy

    2020 — SENHANCE AND DIGITAL LAPAROSCOPY ; RECOGNIZED AS KEY COMPONENTS FOR ROBOTIC GROWTHT™="s=nver'= WEARE FOCUSED ON + Expand the number of sites using | Publication of evidence supporting | = Scene cognition and Augmented the Senhance System in key Senhance value propositions Inteligence technolo

  14. Slide 14: Strong, Broad-Based Clinical Performance

    Slide 14: Strong, Broad-Based Clinical Performance

    STRONG, BROAD-BASED CLINICAL PERFORMANCE SENHANCE DEMONSTRATING STRONG CLINICAL PERFORMANCE ACROSS THE THREE MAJOR GEOGRAPHIES Wrensenterix GLOBAL CLINICAL CASE VOLUME TREND 2019/2020 CASE MIX ROW MUS Asia Gynecology 1,612 iy _ Colorectal 11% * TransEnerix Estimates ang YTD Actual

  15. Slide 15: The First Machine Vision System in Robotic Surgery

    Slide 15: The First Machine Vision System in Robotic Surgery

    THE FIRST MACHINE VISION SYSTEM IN ROBOTIC SURGERY Wransenterix LEADING THE WAY IN AUGMENTED INTELLIGENCE AND MACHINE VISION IN SURGERY SENHANCE INTELLIGENT SURGICAL UNIT (ISU) >! FDAS10(k) Approved In Clinical use in in March 2020 the US 3D POINT TO POINT CRITICAL STRUCTURE DEFECT IDENTIFICATION AN

  16. Slide 16: General Surgery Opportunity in the U.S.

    Slide 16: General Surgery Opportunity in the U.S.

    GENERAL SURGERY OPPORTUNITY IN THE U.S. SS ee GROWTH IN GENERAL SURGERY MUST COME FROM LAPAROSCOPIC. MIS PROCEDURES US Laparoscopic Procedures by Type = Based on current Senhance FDA 510(k) aeentectomy approval, 1.4M procedures are addressable in the US Bariatric FDA Review * In-Process . 7 - * Appr

  17. Slide 17: Financial Overview & Key Operational Accomplishments

    Slide 17: Financial Overview & Key Operational Accomplishments

    WransEnterix Financial Overview & Key Operational Accomplishments

  18. Slide 18: 2020 Operational Highlights

    Slide 18: 2020 Operational Highlights

    2020 OPERATIONAL HIGHLIGHTS VWransenterix SIGNIFICANT OPERATIONAL PROGRESS YEAR TO DATE Eight Senhance lease agreements signed, 6 clinical programs initiated and completed ~900 cases YTD Filed and received FDA clearance for Augmented Intelligence(Al) and machine vision system, Intelligent Surgical U

  19. Slide 19: Financial Highlights

    Slide 19: Financial Highlights

    FINANCIAL HIGHLIGHTS Wransenterix PRUDENTLY MANAGING CASH TO FUND EXECUTION Pro-forma cash of $29.9M' \ Debt-free, except for government promissory note Zz Completed restructuring expected to reduce cash burn by 37% in FY2020 compared to FY2019 l Reduced operating expenses by 15% or $2.4M in Q2 2020

  20. Slide 20: = acErcerie

    Slide 20: = acErcerie

    = acErcerie

Source: SEC EDGAR · 8-K filed Sep 15, 2020

More decks from Asensus Surgical Inc